Safety of Drugs During Previous and Current Coronavirus Pandemics: Lessons for Inflammatory Bowel Disease

被引：10
|
作者：
Sebastian, S. [1 ,2 ]
Gonzalez, H. A. [1 ]
Peyrin-Biroulet, L. [3 ,4 ]
机构：
[1] Hull Univ Teaching Hosp NHS Trust, IBD Unit, Kingston Upon Hull, N Humberside, England
[2] Hull York Med Sch, Kingston Upon Hull, N Humberside, England
[3] Nancy Univ Hosp, Dept Gastroenterol, Vandoeuvre Les Nancy, France
[4] Lorraine Univ, INSERM, U1256, NGERE, Vandoeuvre Les Nancy, France
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷 / 11期
关键词：
IBD; safety; COVID-19; RESPIRATORY SYNDROME-CORONAVIRUS; CRITICALLY-ILL PATIENTS; PAPAIN-LIKE PROTEASE; CORTICOSTEROID TREATMENT; SARS CORONAVIRUS; OPPORTUNISTIC INFECTIONS; MONOCLONAL-ANTIBODY; DISTRESS-SYNDROME; CLINICAL-COURSE; VIRAL LOAD;
D O I：
10.1093/ecco-jcc/jjaa120
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
The coronavirus 2019 [COVID-19] pandemic has posed challenges in the routine care of patients with inflammatory bowel disease [IBD]. One of the key challenges is quantification of the risks of immunosuppressive and biological therapies in IBD patients during the pandemic.The similarities and differences between previous coronavirus outbreaks and the pathobiology of the infections can give useful information in understanding the risks, and perhaps potential beneficial aspects of drugs used in IBD. Although clinical, immunological and pharmacological data from the experience with previous coronavirus outbreaks cannot be automatically translated to predict the safety of IBD therapies during the COVID-19 pandemic, the signals so far from these outbreaks on IBD patients who are on immunomodulators and biologics are reassuring to patients and clinicians alike.
引用
收藏
页码：1632 / 1643
页数：12
相关论文
共 50 条
  • [1] Optimizing the use of current drugs for inflammatory bowel disease
    D'Haens, G
    [J]. INFLAMMATORY BOWEL DISEASE: TRANSLATION FROM BASIC RESEARCH TO CLINICAL PRACTICE, 2005, 140 : 180 - 185
  • [2] Current and emerging drugs for the treatment of inflammatory bowel disease
    Triantafillidis, John K.
    Merikas, Emmanuel
    Georgopoulos, Filippos
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2011, 5 : 185 - 210
  • [3] Safety of biological drugs for inflammatory bowel disease in elderly patients
    Suarez Ferrer, C. J.
    Mesonero, F.
    Caballol, B.
    Ballester, M. P.
    Baston Rey, I.
    Castano Garcia, A.
    Miranda Bautista, J.
    Saiz Chumillas, R.
    Benitez, J. M.
    Sanchez Delgado, L.
    Lopez-Garcia, A.
    Rubin de Celix, C.
    Lopez Sanroma, A.
    Martin-Arranz, M. D.
    Fernandez-Clotet, A.
    Merino Murgui, V.
    Calvino Suarez, C.
    Florez, P.
    Lobato Matilla, M. E.
    Sicilia, B.
    Soto Escribano, P.
    Maroto Martin, C.
    Alonso Abreu, I.
    Melcarne, L.
    Plaza Santos, R.
    Marques Cami, M.
    Caballero Mateos, A.
    Gomez Diez, C.
    Calafat, M.
    Alonso Galan, H.
    Vega Villaamil, P.
    Castro Senosiain, B.
    Guerro Moya, A.
    Rodriguez Diaz, C. Y.
    Spicakova, K.
    Mancenido Marcos, N.
    Molina, G.
    De Castro, L.
    Manosa Ciria, M.
    Barreiro-De Acosta, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I400 - I401
  • [4] Safety of biological drugs for inflammatory bowel disease in elderly patients
    Suarez Ferrer, C. J.
    Mesonero, F.
    Caballol, B.
    Ballester, M. P.
    Baston Rey, I.
    Castano Garcia, A.
    Miranda Bautista, J.
    Saiz Chumillas, R.
    Benitez, J. M.
    Sanchez Delgado, L.
    Lopez-Garcia, A.
    Rubin de Celix, C.
    Lopez Sanroma, A.
    Martin-Arranz, M. D.
    Fernandez-Clotet, A.
    Merino Murgui, V.
    Calvino Suarez, C.
    Florez, P.
    Lobato Matilla, M. E.
    Sicilia, B.
    Soto Escribano, P.
    Maroto Martin, C.
    Alonso Abreu, I.
    Melcarne, L.
    Plaza Santos, R.
    Marques Cami, M.
    Caballero Mateos, A.
    Gomez Diez, C.
    Calafat, M.
    Alonso Galan, H.
    Vega Villaamil, P.
    Castro Senosiain, B.
    Guerro Moya, A.
    Rodriguez Diaz, C. Y.
    Spicakova, K.
    Mancenido Marcos, N.
    Molina, G.
    De Castro, L.
    Manosa Ciria, M.
    Barreiro-De Acosta, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I400 - I401
  • [5] Safety of Thiopurines and Anti-TNF-α Drugs During Pregnancy in Patients With Inflammatory Bowel Disease
    Casanova, M. J.
    Chaparro, M.
    Domenech, E.
    Barreiro-de Acosta, M.
    Bermejo, F.
    Iglesias, E.
    Gomollon, F.
    Rodrigo, L.
    Calvet, X.
    Esteve, M.
    Garcia-Planella, E.
    Garcia-Lopez, S.
    Taxonera, C.
    Calvo, M.
    Lopez, M.
    Ginard, D.
    Gomez-Garcia, M.
    Garrido, E.
    Perez-Calle, J. L.
    Beltran, B.
    Piqueras, M.
    Saro, C.
    Botella, B.
    Duenas, C.
    Ponferrada, A.
    Manosa, M.
    Garcia-Sanchez, V.
    Mate, J.
    Gisbert, J. P.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 (03): : 433 - 440
  • [6] Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: Current perspectives
    Cipolla, G
    Crema, F
    Sacco, S
    Moro, E
    De Ponti, F
    Frigo, G
    [J]. PHARMACOLOGICAL RESEARCH, 2002, 46 (01) : 1 - 6
  • [7] Safety of Tioguanine During Pregnancy in Inflammatory Bowel Disease
    van den Berg, Sophie A.
    de Boer, Marjon
    van der Meulen-de Jong, Andrea E.
    Jansen, Jeroen M.
    Hoentjen, Frank
    Russel, Maurice G. V. M.
    Mahmmod, Nofel
    van Bodegraven, Adriaan A.
    van der Woude, C. Janneke
    Mulder, Chris J. J.
    de Boer, Nanne K. H.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 (02): : 159 - 165
  • [8] Drugs for Inflammatory Bowel Disease
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1680): : 105 - +
  • [9] Drugs for Inflammatory Bowel Disease
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2014, 56 (1448): : 59 - 66
  • [10] Drugs for Inflammatory Bowel Disease
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2018, 60 (1550): : 107 - 114
12345